Literature DB >> 32439687

Reply to Baud and Houzé, "Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?"

E Wenzler1, M Biagi2, X Tan2, D A Butler2.   

Abstract

Year:  2020        PMID： 32439687      PMCID： PMC7269460          DOI： 10.1128/AAC.00401-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  43 in total

Review 1.  New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding.

Authors:  Jacques Chanard; Sylvie Lavaud; Christine Randoux; Philippe Rieu
Journal:  Nephrol Dial Transplant       Date:  2003-02       Impact factor: 5.992

2.  Adsorption of amikacin, a significant mechanism of elimination by hemofiltration.

Authors:  Qi Tian; Charles D Gomersall; Margaret Ip; Perpetua E Tan; Gavin M Joynt; Gordon Y S Choi
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

3.  Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?

Authors:  Frédéric J Baud; Pascal Houzé
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

4.  Longitudinal hemodiafilter performance in modeled continuous renal replacement therapy.

Authors:  Deborah A Pasko; Mariann D Churchwell; Noha N Salama; Bruce A Mueller
Journal:  Blood Purif       Date:  2011-03-02       Impact factor: 2.614

5.  Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Markus Heep; Michael Schleimer; Erhard Weidekamm; Tom Brown; Michael Roehrle; Christoph Beglinger
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

6.  Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects.

Authors:  Amit Desai; Takao Yamazaki; Albert J Dietz; Donna Kowalski; Christopher Lademacher; Helene Pearlman; Shahzad Akhtar; Robert Townsend
Journal:  Clin Pharmacol Drug Dev       Date:  2016-08-04

7.  Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.

Authors:  Robert W Townsend; Shahzad Akhtar; Harry Alcorn; Jolene K Berg; Donna L Kowalski; Salim Mujais; Amit V Desai
Journal:  Eur J Clin Pharmacol       Date:  2017-03-07       Impact factor: 2.953

8.  No Dose Adjustment for Isavuconazole Based on Age or Sex.

Authors:  Amit V Desai; David Han; Donna L Kowalski; Christopher Lademacher; Helene Pearlman; Takao Yamazaki
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

9.  Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).

Authors:  Laura L Kovanda; Amit V Desai; Qiaoyang Lu; Robert W Townsend; Shahzad Akhtar; Peter Bonate; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

10.  Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam.

Authors:  Fekade B Sime; Saurabh Pandey; Nermin Karamujic; Suzanne Parker; Elizabeth Alexander; Jeffery Loutit; Stephanie Durso; David Griffith; Jeffrey Lipman; Steven C Wallis; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191
View more
  2 in total

1.  Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.

Authors:  Eric Wenzler; David Butler; Xing Tan; Takayuki Katsube; Toshihiro Wajima
Journal:  Clin Pharmacokinet       Date:  2021-11-18       Impact factor: 5.577

2.  Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy.

Authors:  Lauren Andrews; Scott Benken; Xing Tan; Eric Wenzler
Journal:  BMC Nephrol       Date:  2021-01-30       Impact factor: 2.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.